Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, announced that the company plans to explore the potential to develop a novel monkeypox vaccine using its norovirus shell and protrusion (S&P) virus-like particle (VLP) platform.
The Company’s S&P platform is currently being utilized to develop vaccine candidates across multiple diseases, including BWV-101 for influenza, BWV-301 for gastroenteritis via norovirus or rotavirus infection, and BWV-302 for malaria. In this new effort, BWV will attempt to present monkeypox antigens within the S&P platform to potentially create a vaccine candidate capable of protecting individuals against monkeypox disease.
Read more here